semaglutide plus cagrilintide Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study Color:Rose Gold BPC-157 Reality Check — Features: 12/24

semaglutide plus cagrilintide Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study Color:Rose Gold BPC-157 Reality Check — Features: 12/24

BPC-157 Reality Check — Opt-In | Mike T Nelson

NAD(+) metabolism, stemness, the immune response, and oncology research models [PMID: 33384409] Laboratory literature summary: NAD(+) metabolism, stemness, the immune response, and oncology research models

Features: 12/24

Color:Rose Gold

This disconnect is not unique to BPC-157, but reflects a broader trend within the biohacking movement, where enthusiasm and anecdotal claims for emerging therapies can sometimes outpace the pace of clinical research and regulatory review